ArticleFrontiers in pharmacology2026
Placental alkaline phosphatase promotes lipid accumulation and fibrosis in ligamentum flavum hypertrophy and represents a potential target for statin repurposing.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Lumbar spinal stenosis is a prevalent degenerative disorder driven primarily by ligamentum flavum hypertrophy. Emerging evidence links ectopic lipid accumulation to fibrotic remodeling and suggests a potential contribution of immune dysregulation. However, the molecular targets connecting lipid accumulation with ligamentum flavum fibrosis remain incompletely defined. We sought to evaluate the underlying mechanisms of lipid-lowering drug targets in lipid-associated ligamentum flavum fibrosis. Methods: We applied two-sample Mendelian randomization (MR), summary-data-based MR, and Bayesian colocalization to evaluate the associations of genetically proxied levels of 213 lipid-lowering drug target proteins with lumbar spinal stenosis risk. Candidate targets were evaluated Results: MR identified three proteins increasing disease risk, with placental alkaline phosphatase (ALPP) consistently replicating across platforms (colocalization at rs12478529, PP.H4 = 0.9979). Genetically inferred mediation analysis suggested that selected immune-cell traits may partially mediate the association between ALPP and lumbar spinal stenosis. Molecular dynamics simulations and cellular thermal shift assays supported target engagement of atorvastatin and simvastatin with ALPP. In clinical specimens, ALPP was upregulated in hypertrophied tissues, co-localizing with fibrosis and lipid accumulation. Conclusion: Our findings identify ALPP as a genetically supported candidate associated with LSS and link it to lipid accumulation and fibrosis. Computational and CETSA findings support possible target engagement of statins with ALPP and attenuate lipid accumulation and fibrosis, supporting ALPP as a potential mediator of their effects and statin repurposing for LSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.